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Abstract
Liver fibrosis is a worldwide clinical issue. It has been well established that activated hepatic stellate cells (HSCs) are
responsible for excessive extracellular matrix (ECM) deposition in chronically damaged livers. The identification of key
elements that control HSCs activation will help to further our understanding of liver fibrosis and improve the outcome of
clinical treatment. This study demonstrates that N-Myc downstream-regulated gene 2 (NDRG2) is a potential regulator of
liver fibrosis as NDRG2 mRNA and protein levels were reduced during HSCs activation. In addition, enhanced NDRG2
expression reduced Smad3 transcription and phosphorylation, which inhibited HSCs activation by blocking the TGF-b1
signal. Moreover, NDRG2 contributed to an increase in the ratio of matrix metalloproteinase 2 (MMP2) to tissue inhibitor of
matrix metalloproteinase 2 (TIMP2), which may facilitate the degradation of the ECM. In dimethylnitrosamine (DMN)-
induced fibrotic rat livers, adenovirus-mediated NDRG2 overexpression resulted in decreased ECM deposition and improved
liver function compared with controls. In conclusion, the present findings indicate that the modulation of NDRG2 is a
promising strategy for the treatment of liver fibrosis.
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Introduction
Liver fibrosis is a major medical problem of liver diseases,
especially in Asian countries. Chronic hepatitis, metabolic
disorders, genetic mutations and cholestatic diseases are common
causes of liver fibrosis and even cirrhosis and hepatocellular
carcinoma (HCC) [1,2]. Substantial improvements in the
treatment of liver fibrosis have been achieved due to continued
studies [3,4,5], thereby prompting us to explore the mechanisms
involved in the development of liver fibrosis and potential
therapies that could inhibit the progression of fibrosis.
HSCs play a central role in liver fibrosis. In normal liver, HSCs
are in a quiescent state and their main function is to store
retinoids. However, during the development of hepatic fibrosis,
chronic liver damage leads to HSCs activation, characterized by a
transformation from the quiescent state to a proliferative,
contractile and fibrogenic myofibroblast-like phenotype that
terminates in excessive hepatic matrix deposition, liver function
impairment, cirrhosis and organ failure [6,7].
The activation of HSCs is finely regulated by multiple pathways
and factors, and of these, TGF-b1/Smad signaling is one of the
major pathways in charge of HSCs activation, type I collagen
expression and deposition. TGF-b1 binds to its receptor, leading
to the phosphorylation of the intracellular mediators Smad2 and
Smad3, which then form hetero-oligomers with a common
mediator, Smad4. The complex then translocates from the
cytoplasm to the nucleus to regulate gene transcription. The
expression of inhibitory Smad7, which interacts with a group of
ubiquitin ligases termed Smurf and degrades the TGF-b receptors
through proteasomal and lysosomal pathways, is also induced by
TGF-b signaling as part of a negative feedback loop [8,9]. In
addition, TGF-b1 regulates the expression of matrix metallopro-
teinases (MMPs) and tissue inhibitor of matrix metalloproteinases
(TIMPs). MMPs are endogenous peptidases capable of degrading
various components of the basement membrane while TIMPs
inhibit collagen degradation. In the fibrotic liver, the expression of
MMPs and TIMPs are both increased [10] and it is the balance of
MMPs and their tissue inhibitors that determines the progression
and regression of ECM accumulation and liver fibrosis [11,12].
Recently, several studies have revealed that NDRG2 is a potent
factor in regulating liver embryonic development, tissue remod-
eling and carcinogenesis. NDRG2 (GenBank Accession No.
AF159092) belongs to the NDRG family, which comprises four
members, NDRG1-4. Our laboratory initially identified human
NDRG2, a cytoplasmic protein that is down-regulated by MYC
and is involved in cell growth and differentiation, stress and
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NDRG2 is closely involved in liver histogenesis and organogenesis
as NDRG2 mRNA and protein levels are generally lower in the
early stages and markedly higher during the later stages of
histogenesis in mouse and human fetal livers of different
gestational ages [16,17]. Our previous study demonstrated that
NDRG2 could regulate liver regeneration by serving as a cell cycle
and apoptosis regulator. As a new tumor suppressor gene
[18,19,20], NDRG2 also plays a critical role in HCC, in which it
is significantly down-regulated compared to adjacent normal
tissues. Furthermore, high NDRG2 expression levels correlate
positively with tumor differentiation and negatively with clinical
parameters relevant to tumor metastasis. In vitro, it has been shown
that NDRG2 affects the proliferative abilities of HCC cell lines
[21] and antagonizes TGF-b1–mediated HCC cell invasion by
down-regulating MMP2 [22]. Additionally, when determine the
gene expression profile for the whole liver during development of
DMN-induced hepatic fibrosis, Takahara et al [23] found that
NDRG2 was down-regulated in hepatocytes following fibrogen-
esis. Taken together, these data implicate the multiple functions of
NDRG2 in liver under both normal and pathological conditions.
However, to date, the significance of NDRG2 in the development
of liver fibrosis has been little studied.
In the current study, we demonstrated that NDRG2 expression
exhibited an inverse relationship with HSCs activation. In
addition, we have shown that NDRG2 inhibited basal and
TGF-b1–mediated HSCs activation via a reduction in Smad3
phosphorylation. Furthermore, adenovirus-mediated NDRG2
overexpression attenuated rat liver fibrosis and improved liver
function by enhancing ECM degradation via the alteration of
MMP2 and TIMP2 expression. In conclusion, our study is the first
to explore the anti-fibrotic effects of NDRG2 in liver.
Results
NDRG2 shows an inverse relationship with HSCs
activation
The spontaneously immortalized human HSCs cell line, LX-2,
exhibits features typical of stellate cells, while the immortalized rat
HSCs cell line, HSC-T6, exhibits features typical of myofibroblasts
[24]. In this study, NDRG2 was expressed in LX-2 cells and was
mainly localized to the cytoplasm, together with alpha smooth
muscle actin (a-SMA), a marker of HSCs activation (Figure 1A).
Previous studies have demonstrated that HSCs undergo further
activation during growth and expansion on a plastic surface [25],
and using this model we were able to assess the relationship
between NDRG2 expression and LX-2 cell activation. After LX-2
cells grew to confluence, they were trypsinized and replated in
100 mm dishes for further activation. Over the next 12 days,
increased expression of a-SMA was detected, indicating LX-2
activation while, in contrast, NDRG2 mRNA and protein
expression decreased (Figure 1B and C). Similar results were
observed in HSC-T6 cells (Figure S1).
TGF-b1 is a classic stimulator for HSCs activation and collagen
production [26,27]. To confirm the relationship between NDRG2
and HSCs activation further, LX-2 cells were treated with TGF-
b1 for 24 h after serum starvation. As expected, TGF-b1 increased
LX-2 activation, as indicated by enhanced a-SMA levels
compared to controls, while NDRG2 expression was inhibited
(Figure 1D and E).
NDRG2 inhibits HSCs activation
Since NDRG2 was down-regulated during HSCs activation,
adenovirus vectors were used to elevate NDRG2 expression
transiently in LX-2 cells to determine the effect of NDRG2 on
HSCs activation. The results showed that adenoviral vectors
expressing NDRG2 (AdNDRG2) enhanced the level of NDRG2
compared to the negative control b-galactosidase (AdLacZ) group
(Figure 2A and B). Next, the activation level of LX-2 cells was
examined by treating the cells with adenovirus and/or TGF-b1.
After treatment, both the basal and TGF-b1–induced a-SMA
protein levels were decreased by NDRG2 overexpression
(Figure 2C and D). These results indicated that NDRG2 could
inhibit HSCs activation, even when mediated by TGF-b1.
NDRG2 inhibits the TGF-b1/Smad signaling pathway and
alters the relative levels of MMP2 to TIMP2
TGF-b1 signaling is essential for HSCs activation and liver
fibrosis. To gain a better understanding of the molecular
mechanisms involved in the NDRG2-mediated inhibition of
HSCs activation, the mRNA levels of the intracellular mediators
of TGF-b1 signal transduction Smad2, Smad3 and Smad7 were
analyzed. The results demonstrated that the transcription of all
three Smads increased in TGF-b1–treated LX-2 cells; however,
AdNDRG2 only attenuated the increase in Smad3 induced by
TGF-b1, while Smad2 and Smad7 showed no differences among
compared groups (Figure 3A). Furthermore, the protein levels of
Smad2/3/7 as well as the phosphorylation of Smad 2/3 were
upregulated in the presence of TGF-b1 stimulation, while
AdNDRG2 treatment only inhibited the protein level and the
phosphorylation status of Smad3 (Figure 3B).
MMPs and TIMPs contribute to both the progression and
regression of liver fibrosis. In this study, the expression of both
MMP2 and TIMP2 increased during LX-2 activation induced by
TGF-b1; however, after AdNDRG2 infection, MMP2 was
enhanced while TIMP2 levels decreased (Figure 3C) compared
with AdLacZ controls (MMP9 and TIMP1 were undetectable).
Consequently, the ratio of MMP2 to TIMP2 was increased
(Table 1), which is helpful for the regression of ECM accumula-
tion.
NDRG2 attenuates DMN-induced liver fibrosis
To explore the anti-fibrosis role of NDRG2 in vivo, a rat liver
fibrosis model was established by DMN injection. Rats receiving
DMN treatment developed severe fibrosis as shown in a
representative hematoxylin and eosin (H&E) and Sirius Red
stained image (Figure 4A). In addition, the expression of NDRG2
in liver cells decreased while a-SMA positive cells increased
dramatically (Figure 5A), indicating that HSCs had been activated
following DMN treatment.
To determine the infection efficiency of the adenovirus, rats
were injected first with phosphate buffered saline (PBS) or a single
dose of adenoviral vector (4610
9 plaque forming units [PFU])
expressing enhanced green fluorescent protein (AdEGFP) via the
tail vein. Forty-eight hours after injection, over 80% of liver cells
were EGFP-positive compared with the PBS group (Figure S2A),
showing that the adenovirus had a high infection efficiency. In
addition, we found that after administration of the same dose of
AdNDRG2, NDRG2 levels were significantly enhanced in rat
liver from day three to day 14 (Figure S2B) while AdLacZ
treatment had no effect on NDRG2 expression (Figure S2C).
Thus, a single dose of adenovirus was enough to enhance NDRG2
expression, which lasted long enough to produce a therapeutic
effect on liver fibrosis.
After treatment, we observed that, compared with PBS or
AdLacZ injection, AdNDRG2 administration not only elevated
NDRG2 expression in liver cells but also inhibited the expression
of a-SMA (Figure 5), which demonstrated further that NDRG2
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was significantly attenuated as revealed by H&E and Sirius Red
staining (Figure 4A and B). Meanwhile, after AdNDRG2 injection,
the hydroxyproline content, which is an indicator for ECM
deposition, was decreased in the AdNDRG2-treated fibrotic livers
(199.6968.23 mg/mg) compared with the AdLacZ group
Figure 1. NDRG2 is decreased during LX-2 activation. (A) Green (FITC conjugated) represented NDRG2 expression while red (CY3 conjugated)
represented a-SMA expression in LX-2 cells, DAPI (blue)-stained nuclei (4006). Real-time PCR (B) and Western blotting (C) were used to detect the
expression of a-SMA and NDRG2 in LX-2 cells grown to confluence and then replated on 100 mm dishes for 12 days. Real-time PCR (D) and Western
blotting (E) were used to detect the expression of a-SMA and NDRG2 in LX-2 cells following serum starvation and supplementing with 0.2% BSA for
48 hours prior to PBS or TGF-b1 treatment (2.5 ng/ml for 24 hours). b-actin was used as a loading control. All experiments were performed
independently in triplicate. *P,0.05 between compared groups.
doi:10.1371/journal.pone.0027710.g001
Figure 2. NDRG2 inhibits HSCs activation. NDRG2 mRNA (A) and protein (B) level in LX-2 cells assessed 48 hours after PBS or adenovirus
infection. a-SMA mRNA (C) and protein (D) level in LX-2 cells assessed after PBS, TGF-b1 and/or adenovirus infection. b-actin was used as a loading
control. Relative quantifications of a-SMA band intensities, normalized to b-actin levels, were shown below blots. All experiments were performed
independently in triplicate. In (A), *P,0.05 compared with the PBS or AdLacZ group. In (C), *P,0.05 compared with the TGF-b1+AdLacZ group;
**P,0.05 compared with the AdLacZ or PBS group.
doi:10.1371/journal.pone.0027710.g002
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(Figure 4C).
In line with the in vitro results, the data obtained from fibrotic
rats indicated that, following AdNDRG2 treatment, the expression
and phosphorylation of Smad3 decreased while the ratio of
MMP2 to TIMP2 increased (Figure 6) (Table 2), confirming that
the regulatory role of NDRG2 in TGF-b1/Smad signaling and in
the regulation of MMP2 and TIMP2 expression contributes
towards its therapeutic effects in the fibrotic liver.
NDRG2 increases hepatocyte proliferation and improves
liver function
Our previous data demonstrated that AdNDRG2 treatment
induced hepatocyte cell cycle arrest and apoptosis in vitro [28].
However, in the present study, it is important to note that
hepatocytes responded differently to AdNDRG2 in DMN-induced
liver fibrosis. Proliferating cell nuclear antigen (PCNA) staining
and BrdU staining increased in AdNDRG2 group compared with
PBS or AdLacZ group while TUNEL analysis revealed that
AdNDRG2 had no effect on inducing hepatocyte apoptosis
(Figure 7) (Figure S3), which indicating that AdNDRG2 not only
inhibited HSCs activation and ECM accumulation, but also
facilitated the regression of liver fibrosis by enhancing the
proliferation of hepatocytes without inducing apoptosis. Moreover,
AdNDRG2 injection significantly improved hepatic serum
biochemical parameters in the DMN-induced rat fibrotic model
(Table 3).
Discussion
HSCs can undergo further activation either by cultured on
uncoated plastic or treated with TGF-b1. These two models are
well-established techniques for studying hepatic fibrogenesis at the
cellular level. The present data demonstrated a decrease in
NDRG2 expression using both of these methods for HSCs
activation. Previous studies have revealed that the level of NDRG2
expression is linked positively to cell differentiation and negatively
to cell proliferation [16,17,29,30,31], and it is well known that
during chronic liver injury, HSCs activation involves the process of
transdifferentiating from quiescent into proliferative and ECM-
producing myofibroblasts [32]. Thus, the decrease in NDRG2
levels during the HSCs activation process is another evidence for
the regulatory role of NDRG2 on cell differentiation and
proliferation. Taking this into account, whether or not NDRG2
regulates the proliferative ability and transdifferentiation process of
HSCs merits further investigation.
TGF-b1 is a profibrogenic cytokine in the liver. The current
study has shown that NDRG2 inhibited HSCs activation in the
absence and presence of TGF-b1, and in addition, increased the
expression of MMP2 in HSCs. These results differ partly from
Figure 3. NDRG2 affects TGF-b1/Smad signaling pathway and the ratio of MMP2 to TIMP2 in LX-2 cells. (A) Real-time PCR was used to
detect the expression of Smad2, Smad3 and Smad7 in LX-2 cells with TGF-b1 and/or adenovirus treatment. (B) Western blotting was used to detect
the expression of Smad2, phospho-Smad2, Smad3, phospho-Smad3 and Smad7 in LX-2 cells with TGF-b1 and/or adenovirus treatment. (C) Real-time
PCR was used to detect the expression of MMP2 and TIMP2 in LX-2 cells following TGF-b1 and/or adenovirus treatment. b-actin was used as a loading
control. All experiments were performed independently in triplicate. *P,0.05 compared with the TGF-b1 or TGF-b1+AdLacZ group.
doi:10.1371/journal.pone.0027710.g003
Table 1. NDRG2 affects the ratio of MMP2 to TIMP2 in LX-2
cells.
Group MMP2/TIMP2
PBS 1
TGF-b1 0.76460.0003
TGF-b1+AdNDRG2 3.41860.3124
*
TGF-b1+AdLacZ 0.66960.0639
*P,0.05 compared with the TGF-b1o rT G F - b1+AdLacZ group.
doi:10.1371/journal.pone.0027710.t001
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NDRG2 antagonized TGF-b1–mediated HCC invasion by
down-regulating MMP2 expression [22]. However, the previous
study was based on the HCC cell line PLC/PRF/5. Most cases of
HCC develop on a liver fibrosis background [33] and a fibrous
capsule surrounds a typical HCC at an early stage [34]. HCC cells
have to degrade the ECM and basement membrane during the
process of metastasis [35]. Therefore, overexpression of NDRG2
leads to reduced MMP2 and ECM degradation, which subse-
quently, confined HCC to its fibrous septa. Yet, in our study,
AdNDRG2 treatment produced an increase in MMP2 as well as a
decrease of TIMP2. MMP2 activity is regulated at the cell surface
and involves the formation of a tri-molecular complex consisting of
pro-MMP2, MT1-MMP and TIMP-2. All three components of
this complex are expressed by activated HSCs [36]. An increase in
MMPs and TIMPs is common in fibrotic diseases, while an
alteration in the MMP/TIMP expression ratio is known to be
critical in determining matrix remodeling [10]. In this study, the
data from LX-2 cells demonstrated that over-expressing NDRG2
inhibited the expression of TIMP2 and increased MMP2.
Consequently, NDRG2 administration reduced ECM deposition
within the liver parenchyma and alleviated liver fibrosis.
Considering the significance of the TGF-b1/Smad signaling
pathway in regulating fibrogenesis, researchers are trying to block
the TGF-b1/Smad signal in order to suppress liver fibrosis.
Importantly, Smad2 and Smad3 exert their functions depending
on the status of HSCs. TGF-b1 induces the phosphorylation and
nuclear translocation of Smad2 in quiescent HSCs and of Smad3
in transdifferentiated HSCs [37]. In addition, data obtained from
infecting cultured rat HSCs with adenoviruses expressing Smad2 or
Smad3 revealed that Smad3 plays a more important role than
Smad2 in the morphological and functional maturation of
myofibroblasts [38]. In the present study, LX-2 cells could be
regarded as partially activated based on the fact that they
expressed a-SMA under all culture conditions [25]. By infecting
LX-2 cells with adenovirus expressing NDRG2, we found that an
increase in NDRG2 in LX-2 cells caused a decrease in Smad3 and
its phosphorylation in the presence of TGF-b1. In contrast, the
status of Smad2 and Smad7 were not affected. Data obtained from
fibrotic rat livers were also consistent with the in vitro study.
Therefore, the decreased activation and inhibited transdifferentia-
tion of HSCs depend on the suppression of Smad3 after
AdNDRG2 treatment.
A recent study from our laboratory revealed that the
overexpression of NDRG2 in a hepatocyte cell line resulted in
G1/S arrest and apoptosis induction. During the early phase of
liver regeneration in a rat partial hepatectomy (PH) model,
NDRG2 was down-regulated, which may have facilitated
hepatocyte proliferation [28]. Based on these data, we wondered
whether AdNDRG2 treatment could inhibit hepatocyte prolifer-
ation and cause apoptosis in fibrotic rat liver, which were harmful
for liver fibrosis treatment. However, in our current study,
enhanced PCNA and BrdU staining in the fibrotic liver implied
that AdNDRG2 injection increased the proliferation of hepato-
cytes. In addition, TUNEL analysis revealed that there were no
significant differences between the numbers of apoptotic cells in
Figure 4. NDRG2 attenuates DMN-induced liver fibrosis. PBS or adenovirus was injected four weeks after DMN treatment and rats were
sacrificed two weeks after injection. (A) Liver fibrosis was assessed by H&E staining (1006) and Sirius Red staining (406). (B) Semiquantitative analysis
of the Sirius Red staining result. (C) Assay of hydroxyproline content. The data are expressed as hydroxyproline (mg)/wet liver weight (mg). Three
samples were determined from each group. ‘‘normal’’ means rats without treatment. *P,0.05 compared with PBS or AdLacZ group.
doi:10.1371/journal.pone.0027710.g004
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The discrepancies between these two studies may be attributed to
the complexity of the NDRG2 regulation network in different liver
tissue remodeling microenvironments (PH-induced liver regener-
ation compared to DMN-induced liver fibrosis). In addition, both
TGF-b1 and ECM deposition have an anti-proliferative and pro-
apoptotic effect on hepatocytes [39]. Thus, in the current study, it
is possible that AdNDRG2 treatment exerted its therapeutic
function by antagonizing TGF-b1 and subsequently increasing
hepatocyte proliferation without inducing cell apoptosis, processes
essential for treating liver fibrosis and improving liver function.
Collectively, the data reported in this study have demonstrated,
for the first time, that NDRG2 is involved in the regulation of liver
fibrosis. NDRG2 expression correlated inversely with HSCs
activation and, in addition, inhibited TGF-b1–induced HSCs
activation by suppressing Smad3 expression and phosphorylation.
Furthermore, the in vivo study indicated that adenovirus-mediated
NDRG2 treatment could effectively attenuate liver fibrosis and
improve liver function. Thus, it is conceivable that modulating
NDRG2 expression may provide a novel therapy for intervention
in liver fibrosis.
Materials and Methods
Cell lines and cell culture
LX-2 and HSC-T6 cells [24] were kindly provided by Dr Scott
Friedman. Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen Life Technologies, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS, Invitro-
gen) in a humidified atmosphere of 5% CO2 at 37uC.
Immunofluorescence analysis
Cells were seeded in 24-well plates and treated with 4%
paraformaldehyde for 15 min at 4uC. After blocking with 1%
bovine serum albumin (BSA) in PBS containing 0.1% Triton X-
100 for 1 hour at room temperature, the cells were incubated with
primary NDRG2 (Abnova, Taiwan, China) or a-SMA (Abcam,
Cambridge, MA, USA) antibodies overnight at 4uC, followed by
three washes with PBS and incubation for 2 hours with FITC- or
CY3-conjugated secondary antibodies (Boster, Wuhan, China).
Cell nuclei were stained with 4,6-diamidino-2-phenylindole
(DAPI; Molecular Probes, OR).
TGF-b1 treatment
Cells were plated in 100 mm dishes. Once they reached 70%
confluence, the cells were serum starved and supplemented with
0.2% BSA for 48 hours. Next, TGF-b1 (2.5 ng/ml, PeproTech,
Rocky Hill, NJ, USA) was added for 24 hours.
Adenovirus infection
Adenoviral vectors expressing human or rat NDRG2
(AdNDRG2), the negative control, b-galactosidase (AdLacZ),
and enhanced green fluorescent protein (AdEGFP) were pur-
Figure 5. NDRG2 inhibits HSCs activation in DMN-induced liver fibrosis. (A) Immunohistochemistry was used to determine the expression
of NDRG2 (2006) and a-SMA (1006). Real-time PCR (B) and Western blotting (C) were used to detect the expression of a-SMA and NDRG2 in liver
tissues. b-actin was used as a loading control. Relative quantifications of band intensities, normalized to b-actin levels, were shown below blots.
‘‘normal’’ means rats without treatment. *P,0.05 compared with the PBS or AdLacZ group.
doi:10.1371/journal.pone.0027710.g005
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were seeded in 100 mm dishes and treated with AdNDRG2,
AdLacZ or PBS in serum-free DMEM for 2 hours. The medium
was replaced with fresh DMEM supplemented with 10% FBS and
incubated for 48 hours. The multiplicity of infection (MOI) was
40, which was determined according to preliminary experimental
results.
Animals
Seven-week-old male Sprague-Dawley rats weighing between
200 and 225 g were housed individually in cages with a 12 hour
light-dark cycle and given free access to water and standard rat
chow throughout the study. All experimental procedures were
conducted in accordance with the ‘Detailed Rules for the
Administration of Animal Experiments for Medical Research
Purposes’ issued by the Ministry of Health of China and had
received ethical approval (Permit number: SCXK 2007-007) by
the Animal Experiment Administration Committee of the Fourth
Military Medical University (Xi’an, P.R., China). All efforts were
made to minimize animals’ suffering and to reduce the number of
animals used.
Fibrosis model and tissue preparation
Rats were injected intraperitoneally with 1% DMN (10 mg/kg)
for three consecutive days per week for up to five weeks. After 12
DMN injections, rats were infused with PBS or a single dose of
4610
9 PFU of AdLacZ or AdNDRG2 via the tail vein (ten rats in
each group). Two weeks after gene delivery, animals were
sacrificed and liver samples were collected. For 59-Bromo-29-
deoxyuridine (BrdU) staining, one hour before sacrifice, 100 mg
BrdU (Sigma, St. Louis, MO) per kg body weight was injected
intraperitoneally. RNA and protein were extracted directly with
standard techniques described below as soon as the liver samples
were excised. For immunohistochemistry analysis, samples were
fixed in 4% phosphate-buffered formalin for two days and then
embedded in paraffin before 3 mm sections were cut and collected
on glass slides. For apoptosis analysis, samples were fixed with
neutral buffered 4% paraformaldehyde overnight at 4uC, and liver
sections of 10 mm thickness were prepared using a cryostat
microtome (Leica, Solms, Germany) and fixed to poly-L-lysine–
coated glass slides. Sections were stored at -20uC until required.
Immunohistochemistry analysis
Sections were deparaffinized in xylene and dehydrated through
a graduated alcohol series. After incubating with 0.3% H2O2 in
Figure 6. NDRG2 affects the TGF-b1/Smad signaling pathway and the ratio of MMP2 to TIMP2 in rats. (A) Real-time PCR was used to
detect the expression of Smad2, Smad3 and Smad7 in rats with PBS or adenovirus treatment. (B) Western blotting was used to detect the expression
of Smad2, phospho-Smad2, Smad3, phospho-Smad3 and Smad7 in rats with PBS or adenovirus treatment. (C) Real-time PCR was used to detect the
expression of MMP2 and TIMP2 in rats following PBS or adenovirus treatment. b-actin was used as a loading control. ‘‘normal’’ means rats without
treatment. *P,0.05 compared with the PBS or AdLacZ group.
doi:10.1371/journal.pone.0027710.g006
Table 2. NDRG2 affects the ratio of MMP2 to TIMP2 in rats.
Group MMP2/TIMP2
normal 1
PBS 0.74960.0076
AdNDRG2 2.64060.2891
*
AdLacZ 0.61560.0125
*P,0.05 compared with the PBS or AdLacZ group. ‘‘normal’’ means rats without
treatment.
doi:10.1371/journal.pone.0027710.t002
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(pH 6.0) for antigen retrieval and incubated with 10% normal goat
serum in PBS for 1 hour at room temperature to block nonspecific
binding. Then, the sections were incubated with the following
primary antibodies in PBS at 4uC overnight: mouse anti-NDRG2
(1:100; Abnova), mouse anti-PCNA (1:2000; Cell Signaling
Technology, Danvers, MA, USA), rabbit anti-a-SMA (1:100;
Abcam), and mouse anti-BrdU (1:100; Santa Cruz Biotechnology,
CA, USA). After equilibrating to room temperature, sections were
first incubated with biotinylated goat anti-mouse/rabbit IgG
(1:400, Sizhengbo, Beijing, China) for 2 hours and then treated
with a streptavidin-horseradish peroxidase complex (Sizhengbo)
for 1 h at room temperature. Staining was examined by
incubation with 3,39-diaminobenzidine (DAB) and the sections
were counterstained with hematoxylin and viewed under a light
microscope.
Sirius Red staining
Sections were deparaffinized and the slides were incubated for
10 min in celestine blue solution and washed with distilled water
three times. Next, the slides were placed in a solution of saturated
picric acid containing 0.05% Sirius Red for 30 min. After washing
with 100% ethanol, slides were mounted in mounting media and
covered with a coverslip. The results of Sirius Red staining were
quantified with Image-Pro Plus software 6.0 (Media Cybernetics,
L.P., Silver Spring, MD).
Apoptotic cell staining
For apoptosis detection in frozen liver tissue sections, terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labeling (TUNEL) staining was performed as described in
the manufacturer’s instructions (Roche, Indianapolis, IN, USA).
Staining was visualized by fluorescence microscopy (Olympus,
Center Valley, PA).
Hepatic function and hydroxyproline content
An automated analyzer at the Department of Pharmacology in
the Fourth Military Medical University was used to analyze serum
Figure 7. NDRG2 promotes hepatocyte proliferation without inducing apoptosis. (A) Immunohistochemistry and TUNEL staining were
used to determine the expression of PCNA (2006) and cell apoptosis (4006) in normal and DMN-induced fibrotic rat livers following PBS or
adenovirus treatment. Semiquantitative analysis of PCNA staining (B) and TUNEL staining (C). ‘‘normal’’ means rats without treatment. *P,0.05
compared with the PBS or AdLacZ group.
doi:10.1371/journal.pone.0027710.g007
Table 3. NDRG2 improves hepatic serum biochemical
parameters.
Group ALB(g/l) ALT(U/l) AST(U/l)
normal 36.563.2 43.167.2 92.4614.9
PBS 15.461.6 208.269.8 251.4632.7
AdNDRG2 26.664.8
* 156.6625.7
* 173.8610.0
*
AdLacZ 13.160.7 218.7612.4 279.2635.5
*P,0.05 compared with the PBS or AdLacZ group. ‘‘normal’’ means rats without
treatment.
doi:10.1371/journal.pone.0027710.t003
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subjected to acid hydrolysis to measure the hydroxyproline content
according to the Hydroxyproline Testing Kit (Jiancheng, Nanjing,
China) protocol.
Real-time PCR
Total RNA was isolated from each sample using TRIzol reagent
(Invitrogen) and then quantified. The cDNA was synthesized from
5 mg of each RNA sample with a Taqman reverse transcriptase
reagent kit (Applied Biosystems, UK) primed with oligo(dT) and
was then used as a template for real-time quantitative PCR
analysis. The sequences of the primers are listed in Table 4. The
mRNAs were detected with SYBR Green PCR Master Mix and
an ABI PRISM 7500 Sequence Detection System (Applied
Biosystems) using the comparative threshold cycle method for
relative quantification. The PCR reaction consisted of 12.5 ml
SYBR Green PCR Master Mix, 10 pmol of the forward and
reverse primers, and 5 ml of template cDNA in a total volume of
25 ml. The thermal cycling conditions comprised an initial
denaturation step at 95uC for 10 s, followed by 45 cycles at
95uC for 5 s and 60uC for 34 s.
Western blot analysis
Cells were harvested from 100 mm culture dishes. Both cells
and liver tissues were lysed in 200 ml RIPA buffer (0.05 M Tris-
HCl [pH 7.4], 0.15 M NaCl, 0.25% deoxycholic acid, 1%
Nonidet P-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluo-
ride, 10 mg/ml aprotinin and 10 mg/ml leupeptin). Protein
concentrations were measured using the bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL, USA). Proteins were
resolved by SDS-PAGE and transferred to Hybond-ECL
nitrocellulose membranes (Amersham Biosciences, Piscataway,
NJ, USA). The blots were probed with the following primary
antibodies: NDRG2 (Abnova), b-actin, Smad7 (Santa Cruz
Biotechnology), a-SMA (Abcam), Smad2/phospho-Smad2
(pSmad2), Smad3/phospho-Smad3 (pSmad3) (Cell Signaling
Technology), followed by incubation with species-matched
secondary antibodies. The bands were detected using enhanced
chemiluminescence (Pierce) or the Odyssey Imaging System (Li-
Cor Biosciences). Band intensities were quantified with Kodak
Digital Science 1D 3.0 (Eastman Kodak, New Haven, CT).
Statistical analysis
Statistical analyses were performed with SPSS software (version
16.0; SPSS, Chicago, IL, USA) using the t-test and analysis of
variance of independent groups. Statistical significance was based
on a value of P,0.05.
Supporting Information
Figure S1 NDRG2 is decreased during HSC-T6 activa-
tion. (A) NDRG2 was expressed in LX-2 and HSC-T6 cells.
Western blotting (B) and real-time PCR (C) were used to detect the
expression of a-SMA and NDRG2 in HSC-T6 cells grown to
confluence and then replated on 100 mm dishes for 12 days. b-
actin was used as a loading control. All experiments were
performed independently in triplicate. *P,0.05 between com-
pared groups.
(TIF)
Figure S2 Adenovirus has a high infection efficiency and
significantly enhanced NDRG2 expression in rat liver.
(A) Rats were injected with PBS or a single dose (4610
9 PFU) of
AdEGFP via the tail vein. Then, 48 hours after injection, rats were
sacrificed and liver samples were fixed with neutral buffered 4%
paraformaldehyde overnight at 4uC in the dark. Liver sections
(10 mm thick) were prepared on a cryostat microtome and fixed to
glass slides. Sections were examined directly under a fluorescent
microscope (1006). (B) Rats were treated with a single dose
(4610
9 PFU) of AdNDRG2 or AdLacZ via the tail vein. Over the
next 14 days, rats were sacrificed at the time points indicated.
Liver samples were collected and proteins were extracted directly.
NDRG2 expression was examined by Western blotting. b-actin
was used as a loading control.
(TIF)
Table 4. Primers for Real-time PCR.
Genes Forward primer (59-3 9) Reverse primer (59-3 9)
Human NDRG2 GAGATATGCTCTTAACCACCCG GCTGCCCAATCCATCCAA
a-SMA GACAATGGCTCTGGGCTCTGTAA CTGTGCTTCGTCACCCACGTA
Smad2 TTAACCGAAATGCCACGGTAGAA GCTCTGCACAAAGATTGCACTATCA
Smad3 AGGCGTGCGGCTCTACTACATC CAGCGAACTCCTGGTTGTTGAA
Smad7 TGCTGTGCAAAGTGTTCAGGTG CCATCGGGTATCTGGAGTAAGGA
MMP2 ATGACATCAAGGGCATTCAGGAG TCTGAGCGATGCCATCAAATACA
TIMP2 GACGGCAAGATGCACATCAC GAGATGTAGCACGGGATCATGG
b-actin AGCGAGCATCCCCCAAAGTT GGGCACGAAGGCTCATCATT
Rat NDRG2 ATGGCAGAGCTTCAGGAGG CGGGTGGTTCAGAGCGTAT
a-SMA CCGAGATCTCACCGACTACC TCCAGAGCGACATAGCACAG
Smad2 TTACAGATCCATCGAACTCGGAGA CACTTAGGCACTCGGCAAACAC
Smad3 CCAGATGAACCACAGCATGGA CTACTGTCATGGACGGCTGTGAA
Smad7 CCTTACTCCAGATACCCGATGG CTTGTTGTCCGAATTGAGCTGT
MMP2 TCCCGAGATCTGCAAGCAAG AGAATGTGGCCACCAGCAAG
TIMP2 GACACGCTTAGCATCACCCAGA CTGTGACCCAGTCCATCCAGAG
b-actin ACCGTGAAAAGATGACCCAGAT AACCCTCATAGATGGGCACAGT
doi:10.1371/journal.pone.0027710.t004
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(A) Immunohistochemistry staining was used to determine the
expression of BrdU (2006) in DMN-induced fibrotic rat livers
following PBS or adenovirus treatment. (B) Semiquantitative
analysis of BrdU staining. *P,0.05 compared with the PBS or
AdLacZ group.
(TIF)
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